ClinicalTrials.gg
CompletedNCT03748784OPTICUpdated Aug 8, 2023

ADVM-022 Intravitreal Gene Therapy for Wet AMD

A Phase 1 interventional study of ADVM-022 in Wet Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration, sponsored by Adverum Biotechnologies, Inc.. Completed at 11 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Adverum Biotechnologies, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Blindness with a site in United States — 14 open to participants now, 24 under way, 4 of them phase 3. Blindness · United States.

Enrollment
28th of 62
30 · median 28
Started
2018
with 3 others
Phase 1
3 of 77
none open now
Registered
48th of 77
by date
Lead sponsor
8 of 77
Adverum Biotechnologies, Inc.

Among the 77 studies in Blindness with a site in United States, this one is the 28th largest by enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 1, and was the 48th registered.

Blindness

144 studies on the registry are indexed under Blindness; 33 are open to participants now.

Browse Blindness studies →

Open to participants now

14 of the 77 studies in Blindness with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Blindness studies recruiting now, 13 (65%) set no upper age limit and 4 (20%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Blindness with a site in United States, or all of them as a file.
02

Study summary

ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.

Read the detailed description

This open-label, multicenter, dose-ranging study will evaluate 2 dose levels in up to 30 subjects (15 per dose) with active choroidal neovascularization (CNV) secondary to AMD. Subjects who are under active anti-VEGF treatment and have demonstrated a meaningful response to anti-VEGF therapy will be considered for participation in this study. The primary endpoint for this study is safety and tolerability of ADVM-022. All subjects will continue to be assessed for 104 weeks following treatment with ADVM-022.

03

Conditions studied

  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration

Keywords

  • Choroidal Neovascularizatio
  • ADVM-022
  • CNV
  • ADVM-022-01
  • AAV.7m8
  • Anti-VEGF therapy
  • Blindness
  • Gene therapy
  • Aflibercept (Eylea)
  • Age-Related Macular Degeneration
  • Wet Macular Degeneration
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases
  • AAV Vector
  • Adverum
  • wAMD
  • AMD
  • wet AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50
  • Diagnosis of neovascular (wet) AMD
  • BCVA ETDRS Snellen equivalent between ≤20/32 and ≥20/320 for each cohort
  • Subjects must be under active anti-VEGF treatment for wAMD and received a minimum of 2 injections within 4 months prior to screening
  • Demonstrated a meaningful response to anti-VEGF therapy
  • Willing and able to provide consent

Exclusion criteria

Exclusion Criteria:

  • History of retinal disease in the study eye other than wet AMD
  • Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye, or any condition preventing visual acuity improvement
  • History of retinal detachment (with or without repair) in the study eye
  • History of vitrectomy, trabeculectomy, or other filtration surgery in the study eye
  • Uncontrolled glaucoma in the study eye
  • Any prior treatment with photodynamic therapy or retinal laser for the treatment of wet AMD and any previous therapeutic radiation in the region of the study eye
  • Any previous intraocular or periocular surgery on the study eye within 6 months
  • Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, in the last 6 months
  • Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Dose 1

    6E11 vg of ADVM-022

    Biological: ADVM-022

  • Experimental
    Dose 2

    2E11 vg of ADVM-022

    Biological: ADVM-022

Interventions

  • BiologicalADVM-022

    ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept

    Also known as: AAV.7m8-aflibercept

06

What researchers measure

Primary outcomes

  1. Type, severity, and incidence of ocular and systemic adverse events (AEs)

    Type, severity, and incidence of ocular and systemic adverse events (AEs)

    Time frame: 104 weeks

Secondary outcomes

  1. Change in best corrected visual acuity (BCVA)

    Change in best corrected visual acuity (BCVA)

    Time frame: 104 weeks

  2. Change in central subfield thickness (CST) and macular volume measured by SD-OCT

    Change in central subfield thickness (CST) and macular volume measured by SD-OCT

    Time frame: 104 weeks

  3. Percentage of subjects requiring anti-VEGF injections over time

    Percentage of subjects requiring anti-VEGF injections over time

    Time frame: 104 weeks

  4. Mean number of anti-VEGF injections over time

    Mean number of anti-VEGF injections over time

    Time frame: 104 weeks

  5. Percentage of subjects without intraretinal fluid over time

    Percentage of subjects without intraretinal fluid over time

    Time frame: 104 weeks

  6. Percentage of subjects without subretinal fluid over time

    Percentage of subjects without subretinal fluid over time

    Time frame: 104 weeks

07

Study locations

11 sites
  • Adverum Clinical Site
    Bakersfield, California 93309, United States
  • Adverum Clinical Site
    Beverly Hills, California 90211, United States
  • Adverum Clinical Site
    Golden, Colorado 80401, United States
  • Adverum Clinical Site
    Deerfield Beach, Florida 33064, United States
  • Adverum Clinical Site
    Reno, Nevada 89502, United States
  • Adverum Clinical Site
    Philadelphia, Pennsylvania 19107, United States
  • Adverum Clinical Site
    West Columbia, South Carolina 29169, United States
  • Adverum Clinical Site
    Nashville, Tennessee 37203, United States
  • Adverum Clinical Site
    Abilene, Texas 79606, United States
  • Adverum Clinical Site
    Houston, Texas 77030, United States
  • Adverum Clinical Site
    The Woodlands, Texas 77384, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jun 2022, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2018
First posted
Nov 21, 2018
StartActual
Nov 14, 2018
Primary completionActual
Jun 22, 2022
CompletionActual
Jun 22, 2022
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03748784
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Nov 14, 2018
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022
Last update
Aug 8, 2023

Study contacts

OPTIC Medical Monitor
study chair · Adverum Biotechnologies, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion